Kjell E Öberg

Kjell E Öberg

Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden;, kjell.oberg@medsci.uu.se | Department of Medical Sciences, Uppsala University, 75236 ...

KOL Resume for Kjell E Öberg  (carcinoid, disease, carcinoid syndrome, endocrine, syndrome)


Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden;,

Uppsala University Hospital, Uppsala, Sweden;


Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.


Department of Endocrine Oncology, Uppsala University, Uppsala, Sweden


Uppsala University, 752 36, Uppsala, Sweden


Department of Medical Sciences, Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.

University Hospital, Uppsala University, Uppsala, Sweden


Department of Endocrine Oncology, University Hospital, Uppsala, Sweden;

Uppsala University, Uppsala, Sweden


Sir John Monadh Distinguished Professor, Monash University, Melbourne, Australia

Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany;, NET Centre, St. Vincent's University and Department of Clinical Medicine, St James Hospital and Trinity College, Dublin, Ireland;, Oncoclin Medicos Associados S/S Ltda, São Paulo, Brazil, Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain;, Department of Endocrinology and Metabolism, Hadassah University Hospital, Mevasseret Tsion, Israel;, Department of Surgery, CHU Robert Debré, Reims, France, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands;, Neuroendocrine Tumor Center of Excellence, Rigshospital, Copenhagen University Hospital, Copenhagen, Denmark;, Institut Català d'Oncologia, Barcelona, Spain;, Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden

Research Professor, University of Rhode Island Professor Emeritus, University of Chicago President, MDTEXT.COM, Incorporated South Dartmouth, Massachusetts

Senior Vice President and Dean of the Medical Faculty, Cedars-Sinai Health System, Los Angeles, California

Robert G. Dunlop Professor of Medicine Dean, Raymond and Ruth Perelman School of Medicine Executive Vice President University of Pennsylvania for the Health System Philadelphia, Pennsylvania


Department of Medical Sciences, Centre of Excellence Endocrine Tumors, Uppsala University, Entrance 40, 5th Floor SE-751 85, Uppsala, Sweden


Department of Medical OncologyUniversity Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Medical OncologyHospital Universitario de Burgos, Avenida Islas Baleares 3, 09006 Burgos, SpainDepartment of Endocrine OncologyNational Cancer Institute, Bogotá, ColombiaDepartment of Cancer Research and Molecular MedicineNorwegian University of Science and Technology, 7491 Trondheim, Norway2nd Department of MedicineSemmelweis University, 46, Szentkiralyi Street, H-1088 Budapest, HungaryDepartment of GastroenterologyUniversity Hospital Marburg, Baldinger Strasse, Marburg D-35043, GermanyDepartment of General Internal MedicineSt Columcille's Hospital, Loughlinstown - Co., Dublin, IrelandDepartment of Clinical Sciences and Community Health (DISCCO)University of Milan, Milan, ItalyLaboratory of Endocrine and Metabolic ResearchIstituto Auxologico Italiano IRCCS, Via Zucchi 18, Cusano Milanino (MI) 20095, ItalyDepartment of Endocrine OncologyUniversity Hospital, Uppsala, SwedenUCL Cancer InstituteUCL, Huntley Street, London WC1E 6BT, UK.


Departments of, Medical Sciences and, Surgical Sciences, Uppsala University, and, Department of Radiology, Uppsala University Hospital, Uppsala, Sweden


Department of Medical Sciences Section of Endocrine Oncology (D.G., A.V.T., K.O.), SE-751 85 Uppsala, Sweden

European Neuroendocrine Tumor Society, Berlin, Germany

Endocrine Oncology Unit, Dept of Medicine, Uppsala University, Uppsala, SWEDEN


Prominent publications by Kjell E Öberg

KOL Index score: 19415

Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally ...

Known for Telotristat Ethyl |  Tryptophan Hydroxylase |  Carcinoid Syndrome |  Bm Frequency |  Patients Placebo
KOL Index score: 18165

BACKGROUND: Interferon alpha (IFN-alpha) has antiangiogenic activity, although the underlying mechanism of action is unclear. Because human neuroendocrine (NE) tumors are highly vascularized and sensitive to IFN-alpha, we investigated whether the therapeutic effects of IFN-alpha result from an inhibition of angiogenesis mediated by a decrease in vascular endothelial growth factor (VEGF) gene expression.

METHODS: VEGF gene and protein expression was analyzed in NE tumors by ...

Known for Interferon Alpha |  Endothelial Growth |  Tumor Angiogenesis |  Factor Gene |  Nude Neovascularization
KOL Index score: 15174

BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.

METHODS: We randomly assigned 410 patients who had advanced, low-grade or intermediate-grade pancreatic neuroendocrine tumors with radiologic progression within the previous 12 months to receive everolimus, at a dose of 10 mg ...

Known for Everolimus Placebo |  Advanced Pancreatic |  Neuroendocrine Tumors |  Radiologic Progression |  3 Study
KOL Index score: 15051

BACKGROUND: Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We aimed to assess the combination of everolimus plus octreotide long-acting repeatable (LAR) in patients with low-grade or intermediate-grade neuroendocrine tumours (carcinoid).

METHODS: We did a randomised, double-blind, placebo-controlled, phase 3 study comparing 10 mg per day oral everolimus with placebo, ...

Known for Octreotide Lar |  Carcinoid Syndrome |  Advanced Neuroendocrine Tumours |  3 Study |  Antineoplastic Agents
KOL Index score: 13874

BACKGROUND: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors.

METHODS: We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors ...

Known for Midgut Neuroendocrine |  177ludotatate Patients |  3 Trial |  Progressionfree Survival |  Tumors Octreotide
KOL Index score: 13277

Carcinoid tumours belong to the family of neuroendocrine tumours with a capacity to take up and concentrate amines and precursors as well as peptides, and can thereby be detected by nuclear medicine techniques. These rare tumours are difficult to diagnose at earlier stages because of small size and multiplicity. Computed tomography (CT) and magnetic resonance imaging (MRI) are mostly of benefit for detection of larger primary tumours (1-3 cm) and liver and lymph-node metastases. A ...

Known for Carcinoid Tumours |  Nuclear Medicine |  Detection Staging |  Somatostatin Receptors |  Computed Tomography
KOL Index score: 13119

BACKGROUND: Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management.

PATIENTS AND METHODS: Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical/atypical ...

Known for Pulmonary Carcinoid |  Neuroendocrine Tumor |  Metastatic Disease |  Expert Consensus |  Relevant Literature
KOL Index score: 12963

BACKGROUND: There are no data from prospective studies focused exclusively on patients with advanced lung and thymic carcinoids. We aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alone or in combination, in patients with advanced carcinoids of the lung or thymus.

METHODS: LUNA was a prospective, multicentre, randomised, open-label, phase 2 trial of adult patients (aged >18 years) with advanced (unresectable or metastatic), well ...

Known for Everolimus Combination |  Pasireotide Treatment |  Safety Patients |  Long Acting |  Lung Thymus
KOL Index score: 11794

PURPOSE: Telotristat ethyl, an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome by reducing serotonin production. Telotristat ethyl was evaluated in TELESTAR, a Phase III study for patients who had carcinoid syndrome with at least 4 bowel movements (BMs) per day and who were receiving somatostatin analogue therapy. This interview substudy was conducted to provide insight into the patient experience in TELESTAR and to help understand whether reductions in BM ...

Known for Telotristat Ethyl |  Carcinoid Syndrome |  Patient Experience |  Exit Interviews |  Bm Frequency


Kjell E Öberg: Influence Statistics

Sample of concepts for which Kjell E Öberg is among the top experts in the world.
Concept World rank
treatment gastrointestinal carcinoid #1
disease surgical cure #1
strategyliquid #1
patients bronchial carcinoids #1
combined treatment combination #1
diarrhea increased frequency #1
insulin immunoreaction #1
typical bronchial #1
telestar clinically meaningful #1
hypothyroidism antibodies #1
patients untreated ept #1
cd44negative tumors #1
90yttrium dotatoc #1
cd44s v7 #1
option colonic nets #1
eam ltl #1
patients immunoglobulin isotypes #1
netest positive #1
motilin npk #1
omeprazole tumor cells #1
interferon somatostatin #1
streptozocin combination #1
vmat1delta15 exon #1
advanced age chromogranin #1
molecular profiling gepnets #1
plc beta expression #1
treatment receptorsubtypespecific analogs #1
multinational pilot study #1
carcinoid #1
menins interaction #1
mri 68gassapet #1
mesenteric liver metastases #1
neuroendocrine gut #1
tumors proliferation marker #1
years somatostatin analogues #1
staging carcinoid tumours #1
interf erons #1
patients perceptions questionnaires #1
6 months antibodies #1
efficacy combined streptozotocin #1
positive immunoreactivity egfr #1
netest neuroendocrine tumors #1
nuclear medicine detection #1
interferon relaxation #1
receptorsubtypespecific analogs #1
carcinoid syndrome treatment #1
sclc bpc #1
octreoscan111 spect spect #1
preclinical evaluation advince #1

Key People For Neuroendocrine Tumors

Top KOLs in the world
Kjell E Öberg
neuroendocrine tumors carcinoid syndrome telotristat ethyl
James C Yao
neuroendocrine tumors gastric cancer carcinoid syndrome
Martyn Evan Caplin
neuroendocrine tumors telotristat ethyl carcinoid syndrome
Wouter W de Herder
neuroendocrine tumors somatostatin analogs carcinoid syndrome
Guido Rindi
neuroendocrine tumors endocrine cells transgenic mice
Philippe B Ruszniewski
neuroendocrine tumors chronic pancreatitis liver metastases

Kjell E Öberg:Expert Impact

Concepts for whichKjell E Öberghas direct influence:Neuroendocrine tumors,  Carcinoid syndrome,  Carcinoid tumors,  Telotristat ethyl,  Multiple endocrine,  Neuroendocrine tumours,  Carcinoid tumours,  Carcinoid tumor.

Kjell E Öberg:KOL impact

Concepts related to the work of other authors for whichfor which Kjell E Öberg has influence:Neuroendocrine tumors,  Multiple endocrine,  Carcinoid syndrome,  Liver metastases,  Peptide receptor,  Neoplasia type,  Pancreatic neoplasms.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden;, kjell.oberg@medsci.uu.se | Department of Medical Sciences, Uppsala University, 75236 Uppsala, Sweden | Uppsala University Hospital, Uppsala, Sweden; | Department o

FREE Custom List